Motif Bio (LON:MTFB)‘s stock had its “buy” rating restated by Northland Securities in a research report issued to clients and investors on Tuesday.
Several other analysts also recently issued reports on the company. FinnCap reissued a “buy” rating and set a GBX 100 ($1.36) target price on shares of Motif Bio in a research note on Wednesday, November 22nd. Peel Hunt reissued a “buy” rating on shares of Motif Bio in a research note on Friday, December 22nd. Finally, Beaufort Securities reissued a “speculative buy” rating and set a GBX 110 ($1.49) target price on shares of Motif Bio in a research note on Thursday, November 16th.
Shares of Motif Bio (LON:MTFB) opened at GBX 40.70 ($0.55) on Tuesday. The stock has a market capitalization of $107.24 and a P/E ratio of -156.54. Motif Bio has a 12 month low of GBX 22.50 ($0.31) and a 12 month high of GBX 51.75 ($0.70).
Motif Bio Company Profile
Motif Bio plc is a clinical-stage biopharmaceutical company. The Company is engaged in development of antibiotics, which are designed for treatment of infections caused by multi-drug resistant bacteria. It operates in the development and commercialization of pharmaceutical formulations segment. The Company is focused on development of its product, Iclaprim, for the treatment of the bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains, such as methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant Streptococcus pneumonia (MDRSP).
Receive News & Ratings for Motif Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motif Bio and related companies with MarketBeat.com's FREE daily email newsletter.